HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acitretin in the treatment of erythrokeratodermia variabilis.

Abstract
A patient with erythrokeratodermia variabilis (Mendes da Costa's disease) is presented, and the clinical and histological response to acitretin is described. An initial dose of 35 mg of acitretin and a maintenance dose of 25-35 mg resulted in a pronounced and sustained improvement. Further reduction of the dosage resulted in a relapse within a few days. At the histological level the extensive hyperkeratosis and the moderate dermal inflammatory infiltrate decreased during treatment with acitretin. In comparison with the other retinoids available so far, acitretin is the derivative of first choice in the treatment of erythrokeratodermia variabilis Mendes da Costa.
AuthorsP C van de Kerkhof, P M Steijlen, R J van Dooren-Greebe, R Happle
JournalDermatologica (Dermatologica) Vol. 181 Issue 4 Pg. 330-3 ( 1990) ISSN: 0011-9075 [Print] Switzerland
PMID2150049 (Publication Type: Case Reports, Journal Article, Review)
Chemical References
  • Tretinoin
  • Acitretin
Topics
  • Acitretin
  • Adolescent
  • Erythema (drug therapy, pathology)
  • Female
  • Humans
  • Keratosis (drug therapy, pathology)
  • Tretinoin (analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: